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many countries and are widely reported to be associated with increased risk
of poor maternal and neonatal outcomes. Syndromic STI management is fre-
quently used in pregnant women in low- and middle-income countries, yet its
low specificity and sensitivity lead to both overtreatment and undertreatment.
Etiologic screening for chlamydial, gonorrheal, and/or trichomonal infection
in all pregnant women combined with targeted treatment might be an effec-
tive intervention. However, the evidence base is insufficient to support the
development of global recommendations. We aimed to describe key con-
siderations and knowledge gaps regarding chlamydial, gonorrheal, and
trichomonal screening during pregnancy to inform future research needed
for developing guidelines for low- and middle-income countries.
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Sexually Transmitted Diseases • Volume 47, Number 12, DecembeResults: Adverse maternal-child health outcomes of potential interest are
wide-ranging and variably defined. No completed randomized controlled
trials on etiologic screening and targeted treatment were identified. Evi-
dence from observational studies was limited, and trials of presumptive
STI treatment have shown mixed results. Subgroups that might benefit
from specific recommendations were identified. Evidence on harms was
limited. Cost-effectiveness was influenced by STI prevalence and availabil-
ity of testing infrastructure and high-accuracy/low-cost tests. Preliminary
data suggested high patient acceptability.
Discussion: Preliminary data on harms, acceptability, and feasibility and
the availability of emerging test technologies suggest that etiologic STI
screening deserves further evaluation as a potential tool to improve mater-
nal and neonatal health outcomes worldwide.
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Grant et al.countries. Regional estimates of STI prevalence among pregnant
women vary1: NG, 1.2% (Latin America) to 4.6% (Southern
Africa); CT, 0.8% (Asia) to 11.2% (Latin America); and TV, 3.9%
(Latin America) to 24.6% (Southern Africa). Although it is difficult
to fully elucidate their relative impact, multiple studies have found
associations between these 3 STIs and increased risk of poor mater-
nal and neonatal outcomes (e.g., miscarriage, stillbirth, preterm
birth, low birth weight, and mother-to-child HIV transmission).2–6
Few countries recommend routine screening for chlamyd-
ial, gonorrheal, or trichomonal infection in pregnant women.7
The World Health Organization (WHO) recommends screening
for HIV infection and syphilis8 but has no specific guidelines for
other STIs beyond syndromic management, which limits treat-
ment to symptomatic women.9 The frequently asymptomatic na-
ture of STIs in women is well established,10 and syndromic
management fails to identify most infected women. Syndromic
management has modest sensitivity (40%–75%) and specificity
(54%–76%) for detecting chlamydial and/or gonococcal infec-
tion.10 A study of HIV-infected pregnant women in South Africa
found that only 24% of women who tested positive for a
chlamydial, gonococcal, or trichomonal infection had vaginal
symptoms (sensitivity), whereas 47% of those with symptoms
were negative for all 3 infections (specificity).11 The poor
specificity and sensitivity of syndromic management lead to both
overtreatment and undertreatment. Poor antimicrobial stewardship
may increase the risk of antibiotic resistance.12
The prevalence of and likely adverse outcomes associated
with curable STIs in pregnant women suggest that etiologic STI
screening of all pregnant women followed by targeted treatment
might be beneficial. However, the evidence base around that inter-
vention is insufficient to support the development of global recom-
mendations. The WHO uses a systematic process for developing
guidelines13 based, in part, on the Population, Intervention, Com-
parator, Outcomes (PICO) and Grading of Recommendations, As-
sessment, Development and Evaluations (GRADE) frameworks
for formulating the question and assessing the benefits, harms,
and other relevant factors. This narrative review aimed to describe
key considerations and knowledge gaps regarding etiologic STI
screening during pregnancy using the PICO and GRADE frame-
works. We also aimed to identify key studies in progress that may
contribute to addressing these knowledge gaps. Our goal was to in-
form future research contributing to the evidence needed for devel-
oping guidelines, particularly for low- and middle-income countries.MATERIALS AND METHODS
This narrative review drew on focused PubMed literature
searches, review of WHO and other agency guidelines, and expert
opinion. International public health and clinical experts from aca-
demia, government, industry, and community-based organizations
met on July 14, 2019, in Vancouver, British Columbia, Canada, to
frame the initial inquiry. Presentations and discussion during the
meeting were the initial source of information for the review.
PubMed (https://www.ncbi.nlm.nih.gov/pubmed) and clinical tri-
als registry (https://clinicaltrials.gov and http://www.isrctn.com)
searches conducted through January 20, 2020, were developed it-
eratively based on initial searches using the terms “pregnancy” and
“screening,” and “sexually transmitted infections,” “chlamydia,”
“gonorrhea,” or “trichomonas.” PubMed searches initially focused
on review articles. Reference lists were examined to identify rele-
vant studies. Randomized controlled trials, observational studies,
modeling, and qualitative studies related to STI screening/
treatment and presumptive STI treatment were examined.We limited
our review to studies where the full-text was available in English. Be-
cause this was not a systematic review, literatures searches were not780 Sexually Traconducted systematically, and identified studies and articles were
not assessed using standardized criteria.
We presented findings using the PICO and GRADE Evi-
dence to Decision frameworks for health system/public health de-
cisions14 and for tests in clinical practice and public health.15 The
population (pregnant women in low- andmiddle-income countries),
intervention (etiologic screening for CT, NG, and/or TVof all preg-
nant women followed by treatment and case management of those
with positive test results), and comparator (syndromic STI manage-
ment) were predetermined by the authors to delineate the scope of
the project. We examined the following GRADE domains:
priority/importance, test accuracy, desirable effects (benefits), unde-
sirable effects (harms), resource requirements/cost-effectiveness,
equity, acceptability, and feasibility. We did not formally address
the quality of available evidence or develop recommendations.Findings
Formulating the key question using the PICO format and
selecting outcomes are critical initial steps in the WHO guideline
process.13 (Fig. 1) The population, intervention, and comparator
were selected a priori by the authors. The adverse outcomes of po-
tential interest were wide-ranging. In meta-analyses of associa-
tions between chlamydial infection and adverse pregnancy
outcomes, women with chlamydial infection had increased risk
of preterm labor/birth, perinatal mortality, stillbirth, intrauterine
fetal demise, and newborn low birth weight/birth size compared
with those without chlamydial infection.4,5 The strength of those
associations was attenuated in adjusted analyses and higher-quality
studies. Chlamydial infection was found to increase mother-to-child
HIV transmission by almost 50% in one study.3 A meta-analysis of
trichomonal infection in pregnancy found that infected women had
a 41% increased risk of preterm birth and 51% increase in having
small for gestational age newborns compared with those without
trichomonal infection.2 We did not identify any meta-analyses
on maternal gonococcal infection; however, maternal gonococcal
infection has been associated with preterm birth, low birth weight,
and neonatal eye infections.6
Outcome definitions varied substantially among studies.
Outcomes related to birth size have been examined using (1) mean
birth weight,16 (2) low birth weight categorization based in weight
(<2500 g)17,18 or chest/head circumference,19 or (3) intrauterine
growth restriction categorization based on weight or height
(<10th percentile).18 In some studies, gestational age was mea-
sured using ultrasound, a highly accurate method,20 whereas
others used self-reported date of last menstrual period or fundal
height, which is less accurate. Other outcome measures had simi-
larly variable definitions across studies.
Subgroups
We identified several patient and population-level subgroups
that might benefit from specific recommendations. Pregnant women
living with HIV infection may have higher STI prevalence21 and a
higher risk of poor birth outcomes22 than those without HIV infec-
tion, which may modify the effect of screening interventions. In
malaria-endemic areas, sulfadoxine-pyrimethamine for intermittent
preventive treatment in pregnant women may have some efficacy
against CTandNGand associated adverse birth outcomes.18As such,
local implementation of intermittent preventive treatment ofmalaria23
could also influence the need for specific recommendations. Geo-
graphic heterogeneity in health systems and the distribution of STIs
and HIV infection1 might indicate other identifiers of subgroups.
Figure 2 summarizes the GRADE Evidence to Decision
domains.nsmitted Diseases • Volume 47, Number 12, December 2020
Figure 1. Population, intervention, comparison, and outcome model for etiologic screening for chlamydial, gonorrheal, and/or trichomonal
infection in pregnant women in low- and middle-income countries.
Sexually Transmitted Infections in PregnancyPriority/Importance
Improved maternal-child health is a primary target of the
UN Sustainable Development Goals,24 and addressing STIs will
contribute to meeting these targets. The high prevalence of STIs
in pregnant women in low- and middle-income countries is estab-
lished,1 and treatments are widely available and easy to adminis-
ter.25,26 However, the magnitude of the impact of treating STIs in
pregnant women on poor maternal-child outcomes has not yet
been fully elucidated (see Benefits), a necessary step for establish-
ing this area as a priority for intervention.
Benefits and Desirable Effects
The benefits of etiologic screening and treating curable
STIs in pregnancy in low- and middle-income countries, apart
from syphilis,9 have not been rigorously examined. We did not
identify any completed clinical trials on etiologic gonococcal,
chlamydial, or trichomonal screening in pregnant women in low-
and middle-income countries. Some observational studies from
high-income countries support chlamydial screening for improv-
ing pregnancy outcomes, but generalizability to low- and
middle-income countries is unclear.21 Multiple authors of reviews
and meta-analyses reported that insufficient information on
confounders, including timing of infection versus testing/
treatment, diagnosis of other infections, and other causes of poor
maternal-child health outcomes, complicated the interpretation
of the available evidence.4,21,27
Trials of presumptive STI treatment in pregnant women to
improve maternal/neonatal outcomes provide information thatSexually Transmitted Diseases • Volume 47, Number 12, Decembemay help elucidate the potential impact of screening and treat-
ment.16,17,19 A cluster randomized controlled trial among ~4000
pregnant women in Uganda19 found that one-time treatment with
azithromycin 1 g, cefixime 400 mg, and metronidazole 2 g, which
were effective against NG, CT, TV, chancroid, and bacterial vagi-
nosis, as well as several non-STI pathogens, resulted in a 17% de-
crease in early neonatal deaths and 47% improvement in birth
weight compared with syndromic STI management. No effects
on stillbirth, maternal deaths, or preterm delivery were identified.
Three randomized trials of intermittent treatment of malaria in
pregnancy were relevant. In Malawi,17 pregnant women received
sulfadoxine-pyrimethamine 1500 mg/75 mg for malaria prevention
and azithromycin 1 g, effective against NG, CT, and a variety of
non-STI pathogens, during the second and third trimesters or pla-
cebo. The authors found a 34% decrease in preterm delivery and a
36% decrease in low birth weight among those who received
azithromycin compared with placebo. No differences in perinatal
or neonatal mortality were found. A second trial in Malawi16
that compared presumptive azithromycin 1 g + sulfadoxine-
pyrimethamine 1000 mg/50 mg during the second and third trimes-
terswith placebo + sulfadoxine-pyrimethamine found no significant
impacts on preterm birth, gestational age at birth, mean birth weight,
or perinatal death. In Papua NewGuinea, presumptive azithromycin
1 g + sulfadoxine-pyrimethamine 1500 mg/75 mg compared with
sulfadoxine-pyrimethamine and chloroquine 450 to 600 mg in
~2000 pregnant women resulted in a 26% lower prevalence of
low birth weight and 38% lower risk of preterm delivery.28
Insufficient knowledge of the effects of STIs at different ges-
tational ages on birth outcomes limits our ability to optimize ther 2020 781
Figure 2. Summary of GRADE Evidence to Decision characteristics for etiologic screening and treatment of chlamydial, gonorrheal, and/or
trichomonal infection in pregnant women in low- and middle-resource countries.
Grant et al.timing of etiologic screening and treatment. Administration of pre-
sumptive STI treatment in the aforementioned trials varied from
one-time treatment at any point during pregnancy19 to monthly
treatment during 14 to 26 weeks’ gestation until delivery.17 Even if
successfully treated, women can be reinfected during pregnancy if
partners are not treated. Unfortunately, the effectiveness of partner
management in these settings has not been fully examined. In ad-
dition, the physiologic mechanisms by which chlamydial, gono-
coccal, and trichomonal infection impact birth outcomes are
complex and unclear.21,29
Table 1 shows the status of ongoing studies on the effec-
tiveness of etiologic screening and treatment in pregnancy. Random-
ized controlled trials are underway in China30 and Papua New
Guinea,29 and in the planning stages in Botswana and South
Africa. A prospective cohort study was recently completed in
Brazil.31s A comparative-effectiveness study is in the planning
stages in Ethiopia. Studies in Cameroon,32s Kenya, Tanzania,
and Malawi,33s Mali,34s and Zambia35s are examining the impact
of presumptive STI treatment, usually coupled with preventive
malaria therapy.
Harm and Undesirable Effects
Evidence of harm from etiologic STI screening and treat-
ment studies in low- and middle-income countries was limited.
Publications of large clinical trials on presumptive STI treatment
have not reported worse birth outcomes compared with control in-
terventions.16,17,19,28 In a trial of presumptive treatment in Papua
New Guinea, numbers of adverse events were similar between in
the control and intervention arms.28 In one trial in the United782 Sexually TraStates, treatment of asymptomatic trichomonal infection in pregnant
women was associated with increased preterm birth36s but the se-
lected intervention (two 2-g doses of metronidazole 48 hours apart
at 16–23 and 24–29 weeks’ gestation) was nonstandard.
Harm attributable to antibiotic use during pregnancy is
possible; however, STI treatment guidelines were designed to
minimize potential harm.25,26 Although increasing antibiotic
use can lead to increased antimicrobial resistance, treatment
based on etiological test results rather than syndromic manage-
ment should reduce overtreatment and decrease selective pressure
for antimicrobial resistance. However, the effects on STI antimi-
crobial resistance have not been studied empirically. The presump-
tive STI treatment trial in Zambia35s is investigating antimicrobial
resistance in the vaginal microbiome.
Sexually transmitted infections are often stigmatized12 and
have been associated with intimate partner violence37s and fear of
intimate partner violence.38s,39s However, many studies have re-
ported very high rates of acceptance of partner notification,38s–
41s suggesting that concerns about intimate partner violence and
stigma around STIs were not a significant barrier for most women.
The trial underway in Papua New Guinea29 is examining intimate
partner violence as an adverse event.
Test Accuracy
Culture-based STI testing requires trained laboratory staff,
specialized specimen transport, and equipment, and has long
turn-around times and low sensitivity.42s,43s Consequently, STI diag-
nostics have moved toward molecular testing in many settings.42s
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Sexually Transmitted Infections in Pregnancy
Sexually Transmitted Diseases • Volume 47, Number 12, Decembecan be conducted in low-resource clinical settings at or near the
point-of-care rather than in a laboratory.43s,44s Reported accuracy
of those tests varied substantially, but studies of some platforms
(e.g., GeneXpert, Cepheid, Sunnyvale, CA) have shown accuracies
of >95%.42s,44s Studies in progress on etiologic STI screening are all
using molecular methods for chlamydial and gonococcal screening
(Table 1). Tests for trichomonal infection are either molecular or
immunochromatographic assays.
Resource Requirements
Cheap antibiotics for STI treatment are widely available,
but accurate diagnostic tests are relatively expensive. In 2019,
the Foundation for Innovative New Diagnostics negotiated a
GeneXpert CT/NG test cartridge price of US$16.20/test for low-
and middle-income countries,45s which excludes specimen collec-
tion supplies and the test platform (US$17,000 one-time cost).
Such pricing is well above the US$1/test threshold some experts
have suggested is needed to implement etiologic STI testing in
low- and middle-income countries.43s Substantially lower test ac-
curacies have been reported for more affordable test options.42s,44s
Cost-effectiveness studies in Australia and the United
States compared chlamydial screening in younger pregnant
women with no screening.46s,47s When considering costs associ-
ated with adverse outcomes averted, screening was cost saving at
chlamydial prevalences of 16.9% and 11%, respectively. Neither
study considered overhead/capital costs or long-term population
impacts of infections averted. In addition, the evidence used in
both studies to inform parameters related to short-term health out-
comes was limited.
Different testing strategies could reduce costs and maxi-
mize impact. A modeling analysis of cost and effectiveness com-
pared different antenatal chlamydial and gonococcal screening
strategies in Botswana with syndromic management.48s Having
GeneXpert equipment available at every antenatal care facility
was the most expensive option but resulted in the most infections
treated and cured. Syndromicmanagement was the least expensive
strategy, but it resulted in fewer infections cured and considerable
overtreatment. A hub-and-spoke approach, where testing occurred
at high-volume facilities and low-volume facilities collected spec-
imens and sent them to high-volume facilities for testing, offered
the optimal cost per infection averted. Further examination of the
costs associated with etiologic screening and treatment in preg-
nancy is planned for the etiologic STI screening trials in
Botswana, Papua New Guinea, and South Africa, as well as the
comparative-effectiveness study in Ethiopia and presumptive STI
treatment trials in Mali and Zambia (Table 1)
Equity
A 2015–2016 survey of ministries of health found only 14
countries, of which 11 were high income, with national antenatal
screening policies for gonorrhea or chlamydia.7 Given that preg-
nant women in low- and middle-income countries suffer from a
disproportionate burden of STIs and poor maternal/neonatal out-
comes,24 access to etiologic STI screening could help improve
health equity around reproductive health and maternal/neonatal
outcomes, although the potential magnitude of the impact global
etiologic STI screening on health equity is unclear.
Acceptability
Etiologic STI screening and treatment has been shown to be
highly acceptable to pregnant women in low- and middle-income
countries. In a combined analysis of 1817 pregnant women from
6 different studies, 93.3% of women approached agreed to be
tested.49s Most participants preferred self-collected vaginal swabsr 2020 787
Grant et al.over physician-collected vaginal swabs; same-day test results and
treatment might have increased participation. In a Papua New
Guinea pilot study using self-collected vaginal swabs, nearly all
women approached wanted to participate.50s Findings from a
South African study also suggest very high (>95%) levels of
acceptability.51s Studies in Botswana, Brazil, and Papua New
Guinea are examining acceptability among women, partners,
and health care providers (Table 1).
Including sex partners in etiologic screening and treatment
is necessary to prevent reinfection. Partner notification and treat-
ment has been acceptable to pregnant women in multiple settings
in low- and middle-income countries.38s–41s In one study from
Brazil, 97% of women reported feeling comfortable asking their
partners to attend antenatal care and 54% to 56% of partners did
attend.40s A follow-up study to examine further partner involve-
ment and etiologic screening was recently completed31s (Table 1).
Feasibility
Feasibility must be considered at both the facility and
health system levels. Some etiologic STI tests can be conducted
at or near the point of care, allowing for decentralized diagnostic
services and enabling same-day testing and treatment in
low-resource settings.52s The 6-study combined analysis
discussed previously reported high levels of feasibility across
study sites (overall 96.7%) defined as the percentage of diagnosed
womenwho received treatment.49s The pilot in PapuaNewGuinea
found that etiologic STI testing and treatment could be successfully
implemented with same-day treatment.50s In South Africa, 92% of
172 pregnant women with positive STI test results received
same-day treatment.51s Although all of those studies used molecular
test platforms that require electricity, the findings suggest that
etiologic STI screening and treatment can be operationalized in a
variety of settings.
Despite successes in research studies, access to test technol-
ogies is a substantial barrier to implementing sustainable etiologic
screening globally. The WHO has recommended the GeneXpert
platform to diagnose tuberculosis in low- and middle-income
countries since 2013.53s As a result, many low- and middle-income
countries have some laboratory infrastructure to support molecular
testing usingGeneXpert,53s which could be applied to STI diagno-
sis. However, the costs associated with those tests remain high,
making the need for cost-effectiveness studies critical for deter-
mining feasibility.
Studies in Papua New Guinea29 and South Africa will
examine operational feasibility of etiologic screening in select
clinics (Table 1). In Ethiopia, investigators are examining feasibility
at the regional health system level.54s
DISCUSSION
This review examined the evidence gaps around etiologic
STI screening in pregnancy in low- and middle-income countries
for each of the GRADE criteria to guide ongoing research that
could support the development of international guidelines. We
did not find direct evidence on the impact of etiologic screening
and treatment of gonococcal, chlamydial, and/or trichomonal in-
fections on pregnancy outcomes in low- and middle-income coun-
tries. We found that differences in outcome definitions may
contribute to future challenges with evaluating the evidence for
eventual guidelines. Preliminary data on harms, acceptability,
and feasibility suggest that etiologic STI screening and treatment
hold promise and merit further investigation, although a key chal-
lenge facing potential widespread implementation of this interven-
tion is the high cost of and infrastructure needed for accurate etiologic
STI tests. Potential harms should continue to be investigated but788 Sexually Trashould not be considered a substantial barrier to further research.
Current studies are further examining many of these challenges
and knowledge gaps.
This review had several limitations. First, the focused
search strategies and study selection processes of a narrative re-
view might have missed some relevant studies. Second, we did
not formally rate the quality of the existing evidence because our
focus was on identifying current research gaps. Third, this review
was limited to a subset of common curable STIs, gonorrheal, chla-
mydial, and trichomonal infection. Guidelines for the detection
and treatment of other treatable STIs that impact maternal and neo-
natal outcomes, most notably Mycoplasma genitalium and bacte-
rial vaginosis, are also lacking,1255s but were beyond the scope
of this effort because of limited evidence and testing options, lack
of complete understanding of pathophysiology, and/or limited
treatment options,
Robust intervention trials examining the efficacy and po-
tential harms of etiologic STI screening in antenatal settings are
a priority. Additional research needs include the following:
• Development of consistent outcome measures, particularly for ges-
tational age, birth weight, and pregnancy loss, that allow for com-
parisons across studies and inmeta-analyses of individual-level data
• Systematic recording of malaria prevalence and use of intermit-
tent preventive therapy in affected areas given that such therapy
may be protective against adverse birth outcomes among women
with some STIs
• Integration of partner notification and treatment into interven-
tion trials to examine the role of reinfection and the effectiveness
of strategies such as at-home testing, expedited partner therapy,
and incentives for partner testing
• Investigation of the influence of timing of etiologic STI screen-
ing and treatment during pregnancy as the ideal timing of STI
screening during pregnancy is currently unknown, and there is
ongoing risk of reinfection
• Collection of data on intimate partner violence at study en-
rollment and incidents of violence during studies since inti-
mate partner violence is both a potential confounder and
adverse effect
• Collection of detailed cost data for performing cost-effectiveness
analyses that consider STI prevalence, risk-based profile ap-
proaches to etiologic screening in low-resource settings, and
availability of testing infrastructure to potentially guide the de-
velopment of prevalence- or risk-based recommendations in
resource-limited settings where the unit cost per test may other-
wise be prohibitive
• Collection and dissemination of population-based STI prevalence
data to inform national estimates of STI burden in pregnancy
• Collection of robust data on other factors associated with ad-
verse pregnancy outcomes including other infections such as
HIV, syphilis, M. genitalium, and bacterial vaginosis, maternal
nutrition, maternal history of adverse birth outcomes, and anemia
• Implementation research to examine operational and health sys-
tem optimization for intervention delivery
Global health inequities and the association between STIs
and poor pregnancy and newborn outcomes support the need to
continue to develop and evaluate more effective interventions to
improve maternal and neonatal health worldwide. Although the
magnitude of the effect of STIs on poor maternal-child health out-
comes in low- andmiddle-income countries is still unknown, there
is potential for substantial population-level impacts given the high
prevalence of STIs in pregnant women in low- and middle-income
countries and the relative ease of treatment. The current syndromic
approach to STI management in pregnant women in low- andnsmitted Diseases • Volume 47, Number 12, December 2020
Sexually Transmitted Infections in Pregnancymiddle-incomecountries leads to both underdiagnosis andoverdiagnosis
and treatment. Emerging technologies have created newopportunities
for implementing more effective STI screening and treatment ap-
proaches, which are now being evaluated in large randomized con-
trolled trials. Research focused on addressing key knowledge gaps
identified here will be central to generating a robust evidence base
to inform the development of effective and sustainable interventions
aimed at reducing the burden and consequences of curable STIs in
pregnancy in low- and middle-income countries.
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